Skip to main content

8 Result(s)

within D L Forrest Remove this filter

and

  1. Article

    Open Access

    A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy

    Tyrosine kinase inhibitor (TKI) therapies induce clinical remission with remarkable effects on chronic myeloid leukemia (CML). However, very few TKIs completely eradicate the leukemic clone and persistence of ...

    X Liu, K Rothe, R Yen, C Fruhstorfer, T Maetzig, M Chen, D L Forrest… in Leukemia (2017)

    Download PDF (3114 KB) View Article

  2. No Access

    Article

    Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens

    We analyzed the late outcomes of 429 long-term survivors post allogeneic hematopoietic SCT (allo-HSCT) who received transplant in our center between 1981 and 2002, and were free of their primary disease for ⩾2...

    Y R Abou-Mourad, B C Lau, M J Barnett, D L Forrest… in Bone Marrow Transplantation (2010)

  3. No Access

    Article

    Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML

    Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the o...

    T J Nevill, D E Hogge, C L Toze, S H Nantel, M M Power… in Bone Marrow Transplantation (2008)

  4. No Access

    Article

    Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results

    Outcome is poor with conventional therapy for relapsed transformed non-Hodgkin's lymphoma (NHL). Autologous SCT has been successfully employed; however the impact of allogeneic SCT has not been well defined. W...

    K M Ramadan, J M Connors, A J Al-Tourah, K W Song… in Bone Marrow Transplantation (2008)

  5. No Access

    Article

    Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease

    In all, 30 patients with CLL proceeded to myeloablative allogeneic BMT using related (n=20, 67%) or unrelated (n=10) donors, at the Princess Margaret Hospital (Toronto) (n=20) or the Leukemia/BMT Program of BC (V...

    C L Toze, A Galal, M J Barnett, J D Shepherd, E A Conneally… in Bone Marrow Transplantation (2005)

  6. No Access

    Article

    Characteristics and outcome of patients develo** endocarditis following hematopoietic stem cell transplantation

    Endocarditis is an uncommon complication of hematopoietic stem cell transplantation (HSCT). A retrospective review of 1547 patients who underwent HSCT in Vancouver between January 1986 and December 2001 was pe...

    J Kuruvilla, D L Forrest, J C Lavoie, S H Nantel… in Bone Marrow Transplantation (2004)

  7. No Access

    Article

    Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis

    To establish incidence and risk factors for development of second malignant neoplasms after high-dose chemo/radiotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT), the case files of ...

    D L Forrest, T J Nevill, S C Naiman, A Le, D A Brockington… in Bone Marrow Transplantation (2003)

  8. No Access

    Article

    Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study

    We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administ...

    D L Forrest, K Thompson, V G Dorcas, S H Couban, R Pierce in Bone Marrow Transplantation (2003)